Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Samia Joseph Khoury, M.D.

Co-Author

This page shows the publications co-authored by Samia Khoury and Howard Weiner.
Connection Strength

5.491
  1. Changes in activated T cells in the blood correlate with disease activity in multiple sclerosis. Arch Neurol. 2000 Aug; 57(8):1183-9.
    View in: PubMed
    Score: 0.235
  2. Changes in serum levels of ICAM and TNF-R correlate with disease activity in multiple sclerosis. Neurology. 1999 Sep 11; 53(4):758-64.
    View in: PubMed
    Score: 0.221
  3. Multiple sclerosis: what have we learned from magnetic resonance imaging studies? Arch Intern Med. 1998 Mar 23; 158(6):565-73.
    View in: PubMed
    Score: 0.200
  4. Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2006 Mar 28; 103(13):5048-53.
    View in: PubMed
    Score: 0.174
  5. Mechanisms of acquired thymic tolerance in experimental autoimmune encephalomyelitis: thymic dendritic-enriched cells induce specific peripheral T cell unresponsiveness in vivo. J Exp Med. 1995 Aug 01; 182(2):357-66.
    View in: PubMed
    Score: 0.166
  6. Longitudinal MRI in multiple sclerosis: correlation between disability and lesion burden. Neurology. 1994 Nov; 44(11):2120-4.
    View in: PubMed
    Score: 0.158
  7. Effect of natalizumab treatment on circulating plasmacytoid dendritic cells: a cross-sectional observational study in patients with multiple sclerosis. PLoS One. 2014; 9(7):e103716.
    View in: PubMed
    Score: 0.155
  8. Kappa light chains in spinal fluid for diagnosing multiple sclerosis. JAMA. 1994 Jul 20; 272(3):242-3.
    View in: PubMed
    Score: 0.155
  9. Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development. Mult Scler. 2014 Apr; 20(4):438-44.
    View in: PubMed
    Score: 0.146
  10. Microglia-mediated nitric oxide cytotoxicity of T cells following amyloid beta-peptide presentation to Th1 cells. J Immunol. 2003 Sep 01; 171(5):2216-24.
    View in: PubMed
    Score: 0.146
  11. Acquired tolerance to experimental autoimmune encephalomyelitis by intrathymic injection of myelin basic protein or its major encephalitogenic peptide. J Exp Med. 1993 Aug 01; 178(2):559-66.
    View in: PubMed
    Score: 0.145
  12. Circulating microRNAs as biomarkers for disease staging in multiple sclerosis. Ann Neurol. 2013 Jun; 73(6):729-40.
    View in: PubMed
    Score: 0.144
  13. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain. J Exp Med. 1992 Nov 01; 176(5):1355-64.
    View in: PubMed
    Score: 0.138
  14. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. III. Synergistic effect of lipopolysaccharide. Cell Immunol. 1990 Dec; 131(2):302-10.
    View in: PubMed
    Score: 0.120
  15. A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis. Arch Neurol. 2010 Sep; 67(9):1055-61.
    View in: PubMed
    Score: 0.118
  16. Oral administration of OKT3 monoclonal antibody to human subjects induces a dose-dependent immunologic effect in T cells and dendritic cells. J Clin Immunol. 2010 Jan; 30(1):167-77.
    View in: PubMed
    Score: 0.111
  17. Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology. 2009 Jun 02; 72(22):1922-30.
    View in: PubMed
    Score: 0.109
  18. Incidence and factors associated with treatment failure in the CLIMB multiple sclerosis cohort study. J Neurol Sci. 2009 Sep 15; 284(1-2):116-9.
    View in: PubMed
    Score: 0.108
  19. Daclizumab in treatment of multiple sclerosis patients. Mult Scler. 2009 Feb; 15(2):272-4.
    View in: PubMed
    Score: 0.106
  20. Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci U S A. 2008 Dec 02; 105(48):18889-94.
    View in: PubMed
    Score: 0.105
  21. Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale. Arch Neurol. 2008 Nov; 65(11):1449-53.
    View in: PubMed
    Score: 0.104
  22. CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial. Neurology. 2008 Sep 16; 71(12):917-24.
    View in: PubMed
    Score: 0.103
  23. Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells. Brain. 2008 Jul; 131(Pt 7):1701-11.
    View in: PubMed
    Score: 0.102
  24. Cognitive dysfunction in patients with clinically isolated syndromes or newly diagnosed multiple sclerosis. Mult Scler. 2007 Sep; 13(8):1004-10.
    View in: PubMed
    Score: 0.095
  25. Predicting short-term disability in multiple sclerosis. Neurology. 2007 Jun 12; 68(24):2059-65.
    View in: PubMed
    Score: 0.095
  26. Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J Immunol. 2006 Sep 15; 177(6):4196-202.
    View in: PubMed
    Score: 0.090
  27. Cyclophosphamide modulates CD4+ T cells into a T helper type 2 phenotype and reverses increased IFN-gamma production of CD8+ T cells in secondary progressive multiple sclerosis. J Neuroimmunol. 2004 Jan; 146(1-2):189-98.
    View in: PubMed
    Score: 0.075
  28. Interferon-beta treatment alters peripheral blood monocytes chemokine production in MS patients. J Neuroimmunol. 2002 May; 126(1-2):205-12.
    View in: PubMed
    Score: 0.066
  29. IL-18 is linked to raised IFN-gamma in multiple sclerosis and is induced by activated CD4(+) T cells via CD40-CD40 ligand interactions. J Neuroimmunol. 2002 Apr; 125(1-2):134-40.
    View in: PubMed
    Score: 0.066
  30. Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol). CNS Drugs. 2002; 16(1):1-8.
    View in: PubMed
    Score: 0.065
  31. Increased percentage of IL-12+ monocytes in the blood correlates with the presence of active MRI lesions in MS. J Neuroimmunol. 2001 Sep 03; 119(1):145-9.
    View in: PubMed
    Score: 0.063
  32. Oral salbutamol decreases IL-12 in patients with secondary progressive multiple sclerosis. J Neuroimmunol. 2001 Jul 02; 117(1-2):156-65.
    View in: PubMed
    Score: 0.063
  33. Defective regulation of IFNgamma and IL-12 by endogenous IL-10 in progressive MS. Neurology. 2000 Jul 25; 55(2):192-8.
    View in: PubMed
    Score: 0.059
  34. Serial magnetic resonance imaging in multiple sclerosis: correlation with attacks, disability, and disease stage. J Neuroimmunol. 2000 May 01; 104(2):164-73.
    View in: PubMed
    Score: 0.058
  35. Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone: response to therapy is linked to the duration of progressive disease. Mult Scler. 1999 Dec; 5(6):403-9.
    View in: PubMed
    Score: 0.056
  36. Seasonal variation of interferon-gamma production in progressive multiple sclerosis. Ann Neurol. 1998 Nov; 44(5):824-8.
    View in: PubMed
    Score: 0.052
  37. Identification of MS-specific serum miRNAs in an international multicenter study. Neurol Neuroimmunol Neuroinflamm. 2018 Sep; 5(5):e491.
    View in: PubMed
    Score: 0.051
  38. Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J Clin Invest. 1998 Aug 15; 102(4):671-8.
    View in: PubMed
    Score: 0.051
  39. Pulse cyclophosphamide plus methylprednisolone induces myelin-antigen-specific IL-4-secreting T cells in multiple sclerosis patients. Clin Immunol Immunopathol. 1998 Jul; 88(1):28-34.
    View in: PubMed
    Score: 0.051
  40. Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: increased interleukin-4 production and associated eosinophilia. Ann Neurol. 1997 Sep; 42(3):313-8.
    View in: PubMed
    Score: 0.048
  41. SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts. Mult Scler. 2018 10; 24(11):1485-1498.
    View in: PubMed
    Score: 0.048
  42. Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis. Arch Neurol. 1997 Aug; 54(8):1018-25.
    View in: PubMed
    Score: 0.048
  43. Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci U S A. 1997 Jan 21; 94(2):599-603.
    View in: PubMed
    Score: 0.046
  44. Three-year open protocol continuation study of oral tolerization with myelin antigens in multiple sclerosis and design of a phase III pivotal trial. Ann N Y Acad Sci. 1996 Feb 13; 778:243-50.
    View in: PubMed
    Score: 0.043
  45. Inhibition of T cell responses by activated human CD8+ T cells is mediated by interferon-gamma and is defective in chronic progressive multiple sclerosis. J Clin Invest. 1995 Jun; 95(6):2711-9.
    View in: PubMed
    Score: 0.041
  46. Therapy for multiple sclerosis. Neurol Clin. 1995 Feb; 13(1):173-96.
    View in: PubMed
    Score: 0.040
  47. Treatment of autoimmune diseases by oral tolerance to autoantigens. Adv Exp Med Biol. 1995; 371B:1217-23.
    View in: PubMed
    Score: 0.040
  48. Oral tolerance: a biologically relevant pathway to generate peripheral tolerance against external and self antigens. Chem Immunol. 1994; 58:259-90.
    View in: PubMed
    Score: 0.037
  49. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol. 1994; 12:809-37.
    View in: PubMed
    Score: 0.037
  50. Increased leptin and A-FABP levels in relapsing and progressive forms of MS. BMC Neurol. 2013 Nov 11; 13:172.
    View in: PubMed
    Score: 0.037
  51. Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus. Neurology. 2013 Nov 26; 81(22):1891-9.
    View in: PubMed
    Score: 0.037
  52. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science. 1993 Feb 26; 259(5099):1321-4.
    View in: PubMed
    Score: 0.035
  53. An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity. Sci Transl Med. 2012 Sep 26; 4(153):153ra131.
    View in: PubMed
    Score: 0.034
  54. The impact of lesion in-painting and registration methods on voxel-based morphometry in detecting regional cerebral gray matter atrophy in multiple sclerosis. AJNR Am J Neuroradiol. 2012 Sep; 33(8):1579-85.
    View in: PubMed
    Score: 0.033
  55. Antigen-driven peripheral immune tolerance. Suppression of organ-specific autoimmune diseases by oral administration of autoantigens. Ann N Y Acad Sci. 1991 Dec 30; 636:227-32.
    View in: PubMed
    Score: 0.032
  56. Magnetic resonance disease severity scale (MRDSS) for patients with multiple sclerosis: a longitudinal study. J Neurol Sci. 2012 Apr 15; 315(1-2):49-54.
    View in: PubMed
    Score: 0.032
  57. Brain MRI lesion load at 1.5T and 3T versus clinical status in multiple sclerosis. J Neuroimaging. 2011 Apr; 21(2):e50-6.
    View in: PubMed
    Score: 0.031
  58. The relationship between normal cerebral perfusion patterns and white matter lesion distribution in 1,249 patients with multiple sclerosis. J Neuroimaging. 2012 Apr; 22(2):129-36.
    View in: PubMed
    Score: 0.031
  59. One year activity on subtraction MRI predicts subsequent 4 year activity and progression in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2011 Oct; 82(10):1125-31.
    View in: PubMed
    Score: 0.031
  60. HLA (A-B-C and -DRB1) alleles and brain MRI changes in multiple sclerosis: a longitudinal study. Genes Immun. 2011 Apr; 12(3):183-90.
    View in: PubMed
    Score: 0.030
  61. A putative Alzheimer's disease risk allele in PCK1 influences brain atrophy in multiple sclerosis. PLoS One. 2010 Nov 30; 5(11):e14169.
    View in: PubMed
    Score: 0.030
  62. Population structure and HLA DRB1 1501 in the response of subjects with multiple sclerosis to first-line treatments. J Neuroimmunol. 2011 Apr; 233(1-2):168-74.
    View in: PubMed
    Score: 0.030
  63. HLA B*44: protective effects in MS susceptibility and MRI outcome measures. Neurology. 2010 Aug 17; 75(7):634-40.
    View in: PubMed
    Score: 0.030
  64. Characterization of immunomodulatory properties and accessory cell function of small intestinal epithelial cells. Cell Immunol. 1990 Apr 15; 127(1):26-34.
    View in: PubMed
    Score: 0.029
  65. Smoking and disease progression in multiple sclerosis. Arch Neurol. 2009 Jul; 66(7):858-64.
    View in: PubMed
    Score: 0.027
  66. Rate of brain atrophy in benign vs early multiple sclerosis. Arch Neurol. 2009 Feb; 66(2):234-7.
    View in: PubMed
    Score: 0.027
  67. Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis. J Neuroimaging. 2009 Jan; 19(1):3-8.
    View in: PubMed
    Score: 0.026
  68. Medulla oblongata volume: a biomarker of spinal cord damage and disability in multiple sclerosis. AJNR Am J Neuroradiol. 2008 Sep; 29(8):1465-70.
    View in: PubMed
    Score: 0.025
  69. Serial blood T cell repertoire alterations in multiple sclerosis patients; correlation with clinical and MRI parameters. J Neuroimmunol. 2006 Aug; 177(1-2):151-60.
    View in: PubMed
    Score: 0.022
  70. Kinin B1 receptor expression on multiple sclerosis mononuclear cells: correlation with magnetic resonance imaging T2-weighted lesion volume and clinical disability. Arch Neurol. 2005 May; 62(5):795-800.
    View in: PubMed
    Score: 0.020
  71. Magnetic resonance imaging surrogates of multiple sclerosis pathology and their relationship to central nervous system atrophy. J Neuroimaging. 2004 Jul; 14(3 Suppl):46S-53S.
    View in: PubMed
    Score: 0.019
  72. CTLA-4 is required for the induction of high dose oral tolerance. Int Immunol. 1998 Apr; 10(4):491-8.
    View in: PubMed
    Score: 0.013
  73. Oral administration of myelin induces antigen-specific TGF-beta 1 secreting T cells in patients with multiple sclerosis. Ann N Y Acad Sci. 1997 Dec 19; 835:120-31.
    View in: PubMed
    Score: 0.012
  74. Oral administration of myelin induces antigen-specific TGF-beta 1-secreting T cells in multiple sclerosis patients. Ann N Y Acad Sci. 1997 Apr 05; 815:412-22.
    View in: PubMed
    Score: 0.012
  75. Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J Clin Invest. 1996 Jul 01; 98(1):70-7.
    View in: PubMed
    Score: 0.011
  76. Antigen-specific TGF-beta1 secretion with bovine myelin oral tolerization in multiple sclerosis. Ann N Y Acad Sci. 1996 Feb 13; 778:251-7.
    View in: PubMed
    Score: 0.011
  77. Mechanisms of oral tolerance by MHC peptides. Ann N Y Acad Sci. 1996 Feb 13; 778:338-45.
    View in: PubMed
    Score: 0.011
  78. Induction of immunity and oral tolerance to alloantigen by polymorphic class II major histocompatibility complex allopeptides in the rat. Transplant Proc. 1993 Feb; 25(1 Pt 1):357-8.
    View in: PubMed
    Score: 0.009
  79. Induction of immunity and oral tolerance with polymorphic class II major histocompatibility complex allopeptides in the rat. Proc Natl Acad Sci U S A. 1992 Aug 15; 89(16):7762-6.
    View in: PubMed
    Score: 0.008
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.